{
    "wpid": "WP5494",
    "organisms": ["Homo sapiens"],
    "description": "\"Therapeutic tyrosine kinase inhibitors and anti-EGFR monoclonal antibodies in glioblastoma anti-EGFR mAbs bind the EGFR extracellular domain, preventing EGFR dimerization and subsequent activation. Tyrosine kinase inhibitors (TKIs) target the intracellular TK domain, blocking subsequent receptor tyrosine kinase pathways (RTKs)\" From Figure F3 in https://pmc.ncbi.nlm.nih.gov/articles/PMC10967338.  Derived from https://pfocr.wikipathways.org/figures/PMC10967338__antibodies-13-00025-g003.html",
    "ontology-ids": [
        "DOID:3068",
        "PW:0000754",
        "CL:0000125"
    ],
    "last-edited": "2024-11-12",
    "title": "Tyrosine kinase inhibitors in glioblastoma",
    "authors": ["Eweitz"],
    "revision": "r135815"
}